Gerresheimer AG and Corning Incorporated announced in February 2023 that they were collaborating to “increase global access to the Velocity Vial technology platform”. This new partnership unties Gerresheimer’s expertise with Corning’s Velocity Vial technology with the intention of “addressing the need for high-quality and cost-effective injectable drug filling process”.
Velocity Vials
Velocity Vials lower costs and provide a “streamlined regulatory process” by improving filling-line efficiency by “up to 50%” as a “drop-in solution”. Gerresheimer and Corning state that, in comparison with “conventional vials”, Velocity Vials protect against damage that leads to “particles, breaks, and cracks”.
“The adoption of Velocity Vials has already helped accelerate the delivery of lifesaving treatments and critical drugs to the market.”
Brendan Mosher, VP and General Manager of Corning, is “excited to welcome Gerresheimer as the first partner to join the Velocity Vial technology platform”.
“Over the past two years, we’ve seen first-hand how vital Corning Velocity Vials have been to improving pharmaceutical-manufacturing performance and quality.”
Expertise meets innovation
The companies state that the partnership will combine Gerresheimer’s “extensive glass converting expertise” with Corning’s “innovative” technology. The vials will be produced in Gerresheimer facilities for an international market, becoming available in North America, Europe, and Asia.
Dr Lukas Burkhardt, of Gerresheimer’s Management Board, emphasised that the company is “dedicated” to “offering our customers best-in-class solutions to the industry’s toughest challenges”.
Do you think this partnership will have a significant effect on vaccine development and manufacture? For more on innovative technological partnerships head here, or join us at the World Vaccine Congress in Washington this April.
